Doing Clinton a favor

The industry's "SWAT" team of biotechnology executives made its first visit to Capitol Hill last week while pharmaceutical companies advanced, and sometimes argued over, proposals for restraining drug price increases. Biotechnology company representatives quietly visited members of Congress while the pitch of the debate over health care reforms intensified within the pharmaceutical industry.

After two previous meetings with White House officials, team members G. Kirk Raab of Genentech, Lisa Conte of Shaman Pharmaceuticals Inc., Thomas Wiggans of CytoTherapeutics, Leonard Schleifer of Regeneron, George Rathmann of ICOS, and David Dubbell of Pel-Freeze turned their attention to members of